[ARWR] Arrowhead Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.59 Change: 0.22 (16.06%)

chart ARWR

Refresh chart

Strongest Trends Summary For ARWR

ARWR is in the long-term up 725% above S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company?s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology include Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types. The company is also involved in the development of Adipotide, which is in phase I clinical trial for the treatment of obesity and metabolic disorders; and CRLX-101 that is in phase II clinical trial to treat various cancer types, including relapsed renal cell carcinoma, relapsed ovarian cancer, and non-metastatic rectal cancer. It has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-dr

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.89 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0% Sales Growth - Q/Q-74.27% P/E-1.79
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-52.54% ROE-59.17% ROI-56.98%
Current Ratio9.1 Quick Ratio Long Term Debt/Equity0.01 Debt Ratio0.09
Gross Margin Operating Margin-29638.3% Net Profit Margin-28158.4% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities210 K Cash From Investing Activities4.3 M Cash From Operating Activities-40.57 M Gross Profit
Net Profit-28.68 M Operating Profit-29.63 M Total Assets162.38 M Total Current Assets120.15 M
Total Current Liabilities13.21 M Total Debt870 K Total Liabilities17.63 M Total Revenue40 K
Technical Data
High 52 week20.3 Low 52 week5.16 Last close13.81 Last change-3.76%
RSI41.9 Average true range0.71 Beta0.58 Volume4.6 M
Simple moving average 20 days-1.68% Simple moving average 50 days1.33% Simple moving average 200 days1.16%
Performance Data
Performance Week4.62% Performance Month4.78% Performance Quart-2.88% Performance Half-5.02%
Performance Year134.07% Performance Year-to-date11.19% Volatility daily3.69% Volatility weekly8.25%
Volatility monthly16.91% Volatility yearly58.56% Relative Volume448.74% Average Volume1.67 M
New High New Low

News

2019-04-15 07:30:00 | Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

2019-04-12 12:45:00 | Arrowhead Presents Clinical Data on JNJ-3989 ARO-HBV at The International Liver Congress™

2019-04-12 06:00:00 | Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™

2019-04-11 09:27:01 | 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

2019-03-29 16:30:00 | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635c4

2019-03-27 07:35:00 | Research Report Identifies Criteo S.A, Ferrari N.V, Freshpet, ServiceMaster Global, CSG Systems International, and Arrowhead Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-03-22 16:16:51 | Produce with the most pesticides in your grocery store

2019-03-18 07:30:00 | Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

2019-03-11 07:30:00 | Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia

2019-03-11 02:25:14 | Here's Why Arrowhead Pharmaceuticals Gained 38.2% in February

2019-03-07 08:01:47 | Does Arrowhead Pharmaceuticals, Inc.’s NASDAQ:ARWR CEO Salary Reflect Performance?

2019-03-01 07:30:00 | Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences

2019-02-12 12:00:00 | ARWR’s 2019 Goals Include Data From Several Studies, Initiation of Ph2 ARO-AAT

2019-02-12 08:30:00 | Biotech Stocks Rising

2019-02-08 12:20:00 | Here's Why Arrowhead Pharmaceuticals Gained as Much as 15.8% Today

2019-02-07 23:24:41 | Arrowhead Pharmaceuticals Inc ARWR Q1 2019 Earnings Conference Call Transcript

2019-02-07 22:54:11 | Edited Transcript of ARWR earnings conference call or presentation 7-Feb-19 9:30pm GMT

2019-02-07 17:25:22 | Arrowhead Research: Fiscal 1Q Earnings Snapshot

2019-02-07 16:00:00 | Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results

2019-02-07 08:08:38 | The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut

2019-01-31 07:35:00 | Report: Exploring Fundamental Drivers Behind TD Ameritrade Holding, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Nucor, Portland General Electric, and TrueBlue — New Horizons, Emerging Trends, and Upcoming Developments

2019-01-30 07:00:28 | Have Insiders Been Selling Arrowhead Pharmaceuticals, Inc. NASDAQ:ARWR Shares?

2019-01-24 16:00:00 | Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results

2019-01-22 14:48:29 | 5 Hot Small-Cap Stocks That Are a Bit Too Toasty

2019-01-12 09:07:00 | Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018

2019-01-07 07:30:00 | Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases

2019-01-07 07:30:00 | Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia

2018-12-21 23:19:56 | Arrowhead Research Corp ARWR: Hedge Funds Are Snapping Up

2018-12-17 18:06:00 | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635c4

2018-12-13 11:42:24 | Why Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday

2018-12-12 16:51:00 | Why Arrowhead Pharmaceuticals Surged 11% Higher Today

2018-12-12 08:07:11 | The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel

2018-12-12 07:00:00 | Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Agios Pharmaceuticals

2018-12-12 00:13:58 | Arrowhead Pharmaceuticals ARWR Q4 2018 Earnings Conference Call Transcript

2018-12-11 21:58:29 | Edited Transcript of ARWR earnings conference call or presentation 11-Dec-18 9:30pm GMT

2018-12-11 16:00:00 | Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results

2018-12-11 08:22:15 | The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

2018-12-10 18:18:00 | Here's Why Arrowhead Pharmaceuticals Jumped 14.1% in November

2018-12-04 16:58:09 | J&J Strikes Deal with argenx to Co-Develop Cancer Antibody

2018-11-30 07:25:00 | Detailed Research: Economic Perspectives on Arrowhead Pharmaceuticals, NexGen Energy, ArcBest, Cigna, The Allstate, and Comtech Telecommunications — What Drives Growth in Today's Competitive Landscape

2018-11-27 07:30:00 | Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results

2018-11-26 11:33:36 | Arrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date

2018-11-09 12:00:00 | Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018

2018-11-09 12:00:00 | Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018

2018-11-07 11:23:00 | Here's Why Arrowhead Pharmaceuticals Dropped 33.6% in October

2018-11-01 07:30:00 | Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences

2018-10-31 07:30:00 | Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen

2018-10-23 08:21:00 | Why Investors Are Paying a Premium for These 3 Biotech Stocks

2018-10-23 07:25:00 | Market Trends Toward New Normal in IAC/InterActiveCorp, Eagle Pharmaceuticals, Arrowhead Pharmaceuticals, The Manitowoc, Brookdale Senior Living, and LATAM Airlines Group S.A — Emerging Consolidated Expectations, Analyst Ratings

2018-10-19 11:02:00 | The Rally in Arrowhead Pharmaceuticals Has Been Impressive - Now What?